J Gynecol Oncol.
2018 Nov;29(6):e82. 10.3802/jgo.2018.29.e82.
Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea.
- 2Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. kdyog@amc.seoul.kr
- 3Department of Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- KMID: 2431229
- DOI: http://doi.org/10.3802/jgo.2018.29.e82
Abstract
OBJECTIVE
The impact of beta blockers (BBs) on survival outcomes in ovarian cancer was investigated.
METHODS
By using Korean National Health Insurance Service Data, Cox proportional hazards regression was performed to analyze hazard ratios (HRs) with 95% confidence intervals (CIs) adjusting for confounding factors.
RESULTS
Among 866 eligible patients, 206 (23.8%) were BB users and 660 (76.2%) were non-users. Among the 206 BB users, 151 (73.3%) were non-selective beta blocker (NSBB) users and 105 (51.0%) were selective beta blocker (SBB) users. BB use in patients aged ≥60 years, longer duration use (≥1 year), in patients with Charlson Comorbidity Index (CCI) ≥3, and in cardiovascular disease including hypertension was associated with better survival outcome. These findings were observed in both NSBB and SBB. When duration of medication was analyzed based on number of days, NSBB (≥180 days) was associated with improved overall survival (OS) with a relatively shorter period of use compared to SBB (≥720 days). In multivariate Cox proportional hazards model, longer duration of BB medication (≥1 year) was an independent favorable prognostic factor for both OS and disease-specific survival in ovarian cancer patients.
CONCLUSION
In our nationwide population-based cohort study, BB use was associated with better survival outcomes in ovarian cancer in cases of long term duration of use, in older patients, and in cardiovascular and/or other underlying disease (CCI ≥3).
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Impact of Angiotensin Receptor Blockers, Beta Blockers,Calcium Channel Blockers and Thiazide Diuretics on Survivalof Ovarian Cancer Patients
- Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study
- The Role of Beta Blockers in Treating Hypertensive Patients
- The Role of Catecholamines (Epinephrine/Norepinephrine) and Beta Blocker in Head and Neck Cancer
- Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study
